FRESENIUS KABI NORGE AS
Keywords
pharmaceuticalshospital equipmentorthopedic articles
Organization
- CEO
- JP
Jonas Potyka1976
- Chairman of the board
- JP
Jonas Potyka1976
- Years since formation
- 27 years
- since Oct 30, 1998
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 29
Ownership
- Number of shares and share classes
- 50,670
- 1 share class
- Total number of shareholders
- 1
- person
- Belongs to group of
Financials
- Total operating income 2023
- 2,271,258,715
- NOK
- Annual total result 2023
- 45,817,260
- NOK
- Total equity 2023
- 1,485,114,913
- NOK
Last update: Nov 21, 2024
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
JP 1976 | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
HB 1971 | Board Member | - |
JP 1976 | Chairman | - |
AB | Board Member | - |
MC | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Last update: Nov 22, 2024
Ownership
Company shareholders
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 50,670 | 100 % |
Shares owned by the FRESENIUS KABI NORGE AS
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 100 | 100 % |
Last update: May 24, 2024
Group structure
- Total operating income 2023: NOK 2,271,258,715Operating profit 2023: NOK 36,484,723Employees: 29
Financials
in NOK
Summary
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 2,271,258,715 | 2,021,287,000 | 1,583,265,000 |
Annual Total Result | 45,817,260 | 194,910,000 | 147,703,000 |
Total assets | 1,953,203,929 | 1,993,627,000 | 1,772,253,000 |
Total liabilities | 468,089,016 | 555,485,000 | 429,021,000 |
Total equity | 1,485,114,913 | 1,438,142,000 | 1,343,232,000 |
P&L
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 2,271,258,715 | 2,021,287,000 | 1,583,265,000 |
Total operating costs | 2,234,773,993 | 1,808,854,000 | 1,386,924,000 |
Operating result | 36,484,723 | 212,432,000 | 196,341,000 |
Financial income/costs | 22,305,434 | 43,516,000 | -7,030,000 |
Profit before tax | 58,790,157 | 255,948,000 | 189,311,000 |
Total tax & extraordinary income/cost | 12,972,897 | 61,038,000 | 41,608,000 |
Annual Total Result | 45,817,260 | 194,910,000 | 147,703,000 |
Balance overview
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total fixed assets | 401,486,427 | 508,223,000 | 525,187,000 |
Total current assets | 1,551,717,502 | 1,485,405,000 | 1,247,066,000 |
Total assets | 1,953,203,929 | 1,993,627,000 | 1,772,253,000 |
Short term debt | 442,468,925 | 493,375,000 | 361,748,000 |
Long term debt | 25,620,091 | 62,110,000 | 67,273,000 |
Total liabilities | 468,089,016 | 555,485,000 | 429,021,000 |
Contributed capital | 50,670,000 | 50,670,000 | 50,670,000 |
Retained earnings | 1,434,444,913 | 1,387,472,000 | 1,292,562,000 |
Total equity | 1,485,114,913 | 1,438,142,000 | 1,343,232,000 |
Total equity and liabilities | 1,953,203,929 | 1,993,627,000 | 1,772,253,000 |
Classification
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
G
Main industrial area
Wholesale and retail trade; repair of motor vehicles and motorcycles
46
Activity
Wholesale trade, except of motor vehicles and motorcycles
46.4
Main industrial group
Wholesale of household goods
46.46
Industrial group
Wholesale of pharmaceutical goods
46.460
Industrial group
Wholesale of pharmaceutical goods